Table 29.6

5-Year Relative Survival (Percent), 2009-2015<sup>a</sup>

By International Classification of Childhood Cancer(ICCC)<sup>b</sup> Selected Group and Subgroup<sup>c</sup> and Sex and Age Excluding benign brain and myelodysplastic syndromes

|   | Ages 0-19 by Sex                     |                                      |                                      |   | Both Sexes by Age                           |   |   |   |                                      |  |
|---|--------------------------------------|--------------------------------------|--------------------------------------|---|---|---|---|---|--------------------------------------|--|
| ICCC Group & Subgroup   | Total                                | Male                                 | <u>Female</u>                        | <1  | 1-4   | 5-9   | 10-14   | 15-19   | 0-14                                 |  |
| All ICCC Groups Combined  | 84.1                                 | 83.0                                 | 85.3                                 | 77.7                                      | 85.8  | 83.6  | 83.0  | 85.0  | 83.7                                 |  |
| I Leukemia<br>I(a) Lymphoid leukemia<br>I(b) Acute myeloid leukemia   | 84.1<br>88.5<br>66.0                 | 83.7<br>87.8<br>65.4                 | 84.7<br>89.4<br>66.7                 | 60.1<br>55.9<br>63.9                      | 91.3<br>94.4<br>70.7                        | 90.2<br>92.7<br>70.6                              | 78.6<br>83.5<br>58.3                              | 72.8<br>74.1<br>66.3                              | 86.5<br>90.7<br>65.9                 |  |
| II Lymphomas and reticuloendothelial neo.<br>II(a) Hodgkin lymphoma<br>II(b,c,e) Non-Hodgkin lymphoma   | 93.5<br>97.3<br>89.8                 | 93.7<br>97.3<br>90.9                 | 93.1<br>97.1<br>87.6                 | -<br>-<br>-                               | 88.2<br>94.9<br>86.9                        | 95.3<br>99.4<br>93.7                              | 93.7<br>98.2<br>89.9                              | 93.5<br>96.7<br>88.3                              | 93.5<br>98.4<br>90.8                 |  |
| III CNS & misc intracranial & intraspinal neo. III(a) Ependymomas and choroid plexus tumor III(b) Astrocytoma III(c) Intracranial and intraspinal embryonal tumors III(d) Other gliomas | 74.1<br>81.8<br>81.2<br>64.9<br>59.8 | 73.2<br>81.2<br>80.0<br>63.0<br>63.4 | 75.1<br>82.3<br>82.5<br>67.8<br>56.1 | 58.9<br>80.7 <sup>d</sup><br>81.5<br>26.1 | 75.4<br>79.2<br>90.4<br>58.0<br>53.3        | 70.0<br>79.7 <sup>d</sup><br>77.3<br>77.8<br>41.3 | 79.1<br>81.6 <sup>d</sup><br>81.7<br>76.4<br>72.3 | 76.8<br>90.5<br>75.4<br>67.5 <sup>d</sup><br>83.8 | 73.5<br>80.0<br>82.8<br>64.6<br>53.9 |  |
| IV Neuroblastoma and other peripheral nervous cell tumors $\ensuremath{\text{IV}(a)}$ Neuroblastoma and ganglioneuroblastoma  | 80.6<br>80.5                         | 79.0<br>78.8                         | 82.3<br>82.4                         | 90.5<br>90.5                              | 76.2<br>76.1                                | 78.7<br>78.0                                      | 91.6<br>92.2                                      | 56.8 <sup>d</sup>                                 | 81.4<br>81.2                         |  |
| V Retinoblastoma  | 95.7                                 | 95.5                                 | 95.9                                 | 96.9                                      | 95.0  | -   | -   | -   | 95.7                                 |  |
| VI Renal tumors<br>VI(a) Nephroblastoma and other nonepithelial renal tumor   | 90.7<br>92.4                         | 87.4<br>90.5                         | 93.7<br>94.0                         | 87.6<br>87.5                              | 93.7<br>93.8                                | 90.2<br>91.5                                      | 91.7<br>96.6                                      | 75.0<br>-   | 92.1<br>92.6                         |  |
| VII Hepatic tumors<br>VII(a) Hepatoblastoma   | 75.3<br>82.2                         | 74.0<br>80.2                         | 77.4<br>85.6                         | 87.3<br>87.1                              | 79.6<br>79.4                                | 68.4 <sup>d</sup>                                 | 64.1 <sup>d</sup>                                 | 44.0 <sup>d</sup>                                 | 79.0<br>82.5                         |  |
| VIII Malignant bone tumors VIII(a) Osteosarcoma VIII(c) Ewing tumor and related sarcomas of bone  | 71.1<br>68.0<br>69.9                 | 70.3<br>65.5<br>71.6                 | 72.3<br>71.2<br>67.7                 | -<br>-<br>-                               | 79.2 <sup>d</sup><br>-<br>91.5 <sup>d</sup> | 74.5<br>71.7<br>74.9 <sup>d</sup>                 | 72.0<br>67.6<br>74.1                              | 68.0<br>66.6<br>57.5                              | 73.2<br>69.0<br>76.3                 |  |
| IX Soft tissue and other extraosseous sarcomas IX(a) Rhabdomyosarcoma   | 73.2<br>65.3                         | 70.5<br>65.6                         | 76.3<br>65.1                         | 66.8<br>71.5 <sup>d</sup>                 | 78.0<br>73.7                                | 78.8<br>79.4                                      | 74.4<br>55.8                                      | 68.6<br>44.9                                      | 75.7<br>70.5                         |  |
| X Germ cell & trophoblastic tumors & neo. of gonads $X(a)$ Intracranial and intraspinal germ-cell tumor $X(c)$ Malignant gonadal germ cell tumor  | 92.2<br>91.2<br>96.4                 | 92.9<br>91.2<br>96.3                 | 90.9<br>91.1<br>96.6                 | 83.2<br>-<br>95.4 <sup>d</sup>            | 90.3  | 99.2<br>100.0<br>100.0                            | 91.1<br>90.0<br>97.1                              | 93.0<br>92.5<br>96.0                              | 90.5<br>90.3<br>98.0                 |  |
| XI Other malignant epithelial neo. and melanomas $^{\rm f}$ XI(b) Thyroid carcinoma XI(d) Malignant melanoma  | 93.3<br>99.5<br>94.4                 | 89.9<br>99.7<br>92.9                 | 94.8<br>99.4<br>95.5                 | -<br>-<br>-                               | 90.0<br>-<br>88.1 <sup>d</sup>              | 92.7<br>100.0<br>95.4                             | 92.9<br>99.7<br>95.5                              | 93.6<br>99.4<br>94.5                              | 92.6<br>99.8<br>94.7                 |  |

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2016.

International Classification of Childhood Cancer is based on ICD-O-3. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third Edition. Cancer. April 1, 2005: Vol 103, No. 7, pg 1457-1467.

Classifications are shown for invasive cases only. For ICCC groups and subgroups that include in situ behavior, only invasive cases are shown except as noted.

d The standard error is between 5 and 10 percentage points.

The standard error is greater than 10 percentage points.

Includes in situ urinary bladder tumors.

<sup>-</sup> Statistic could not be calculated due to fewer than 25 cases during the time period. Neoplasms are abbreviated as neo.